YOUR PHARMACOLOGY

RESEARCH SERVICE
PROVIDER
Therapeutic Areas Therapeutics Modalities We Work With

Oncology
Immuno- Biologics Cell Therapy of
oncology CAR-T

Autoimmune
Diseases

More in
development...
Oncolytic Viruses Small Molecules

Pharmacology Service Capabilities

In Vitro
Assay
PD
Profiling

In Vivo Toxicity
Study
PK
Services

Our Models
Humanized Mouse Models
for Immune Oncology and
Autoimmune Disease Drug
Evaluation
• Single/Double/Triple
Humanized Immune Checkpoint
Mouse Model
• Cytokine/Cytokine Receptor
Humanized Mouse Models
Highly Immune-Deficient B-NDG
Mice and Their Variants
• Human Immune Reconstituted
Models Using Human PBMC and
Human CD34+ HSCs Engraftment
• CDX (Cell Line-derived xenografts)
• PDX (Patient-derived xenografts)
Genetically Modified Cell Line
Models for Both In Vivo and In
Vitro Applications
• Humanized Tumor Cell Lines
• Luciferase Reporter Tumor
Cell Lines
THERAPEUTIC AREAS

Immuno-Oncology
Monoclonal Antibody
Anti-hPD-1Treatment of Humanized
PD-1 Mice (B-hPD-1) Bearing MC38
Tumor

Combination Therapy MC38 Cells (Hot Tumor) B16-F10-hPD-L1 Cells (Cold Tumor)

Keytruda and Anti-hOX40

Antibody Treatment of
Humanized PD-1/OX40 Mice
(B-hPD-1/hOX40) Bearing
Different Tumors

Bispecific Antibody
Blinatumomab Treatment
of Humanized CD3e Mice
(B-hCD3e) Bearing MC38-
hCD19 Tumor

CAR-T
CAR-T Efficacy Study Using
B-NDG Based CDX Model

Days Post Treatment Days Post Treatment

Oncology
Highly Immune-Deficient PDX Samples Used in
B-NDG Mouse Model B-NDG Mice
Characteristics of B-NDG Mice • Gastric
• Knock out of IL2Rγ in NOD/SCID mice • Lung
• Complete loss of T, B and NK cells • Pancreatic
• No IgG or IgM in serum • Blood
• Optimal for studies such as human • Esophagus
immune system reconstitution, PDX • Colorectal
models, antibody efficacy evaluations
• Breast

Human Immune System Reconstitution in B-NDG Mouse Model

Monospecific and Bispecific

Antibodies Efficacy Evaluation
Using Human Immune System
Reconstituted B-NDG Mice

Autoimmune Diseases DUPIXENT Treatment Leads to the Reduction of BALF Immune Cells Isolated
from B-hIL4/hIL4Ra Asthma Mice

Biocytogen provides robust

animal models for autoimmune
disease studies including:
• Experimental Autoimmune
Encephalomyelitis (EAE)
Model
Alum/ovalbumin OVA
• Asthma Model Group Mice
sensitization challenge
Drug Dose

• Psoriasis Model 1 C57 Al(OH)3+OVA 2% OVA PBS /

2 B-hIL4/IL4Ra PBS PBS PBS /
3 B-hIL4/IL4Ra Al(OH)3+OVA 2% OVA PBS /
4 B-hIL4/IL4Ra Al(OH)3+OVA 2% OVA DUPIXENT 25mg/kg
PHARMACOLOGY SERVICE CAPABILITIES

In Vivo Study B-h4-1BB Mice with MC38 Tumor Respond to Treatment of Anti-Human 4-1BB Antibodies

• Antibody Efficacy Study

in Immune-competent
Syngeneic Mouse Models
(single or combination
therapy)
• Bispecific Antibody
Efficacy Study
• Small Molecule Efficacy
Study
• CAR-T Efficacy Study in
Highly Immune-deficient
B-NDG Mice

In Vitro Assays Anti-CTLA4 Antibody Antibody-dependent Cellular Cytotoxicity (ADCC) Activity Test

• Drug Cell-Binding Assays

• In Vitro Stimulation Tests
• MLR-Based In Vitro
Stimulation Tests
• In Vitro Killing Assays
(ADCC, CDC)
• Hemolysis/Coagulation
Tests
Pharmacokinetics (PK) Services
• Dose Range Finding
• Drug Administration by Any Route
• Sample Collections Over Specified
Time Points from Blood/Plasma/
Serum and Any Other Tissues
• Blood and Tissue-Specific PK Analysis
for Biotherapeutics Where Detection
Antibodies
• Biodistribution Including Tissue
Collection and Drug Concentration
Determination of Biotherapeutics

Pharmacodynamic (PD) Profiling

• Immune Cell Profiling by Flow Cytometry Analysis (FACS) In Tumor (TILs) and Other Tissues for Lymphoid, Myeloid, and
Other Surface or Intracellular Markers
• Cytokine/Chemokine Profiling by Multiplexed Technologies
• RNA Expression Profiling
• Immunohistochemistry (IHC)
• RO (Receptor Occupancy) Assay
Immune cell and cytokine markers

Toxicity
• Animal Clinical Observations
• Complete Blood Count
• Blood Chemistry Analysis
• Histopathology (FFPE Block
Preparation, H&E, IHC)
• On-Mechanism Toxicity Assays
 Our Models
Single/Double/Triple Immune Checkpoint Humanized Mouse Models
• B- hPD-1 Mice
• B- hCD274(PD-L1) Mice
• B- hCTLA-4 Mice
• B- hTNFRSF4(OX40) Mice
• B- hCD137(4-1BB) Mice
• B- hCD40 Mice
• B-hTNFRSF18(GITR) Mice
• B- hSIRPa Mice
• B- hCD47 Mice
• B- hTIGIT Mice
• B- hLAG-3 Mice
• B- hHAVCR2(TIM-3) Mice
• B- hBTLA Mice
• B- hCD28 Mice
• B- hCD27 Mice
• B- hCD3e Mice
• B- hPD-1/hPD-L1 Mice
• B- hPD-1/hOX40 Mice
• B- hPD-L1/hOX40 Mice
• B- hPD-1/hTIGIT Mice
Mouse Models Under Validation
Other Humanized
Mouse Models
• B-HLA-A2.1 Mice
• B-hSTING Mice
• B-hPD-L2 Mice
• B-hB7-H3 Mice
• B-hCD73 Mice
• B-hCCR2 Mice
• B-hKIT Mice
• B-hST2 Mice
• B-hCD39 Mice
• B-hTNFR2 Mice
• B-hICOSL Mice
• B-hOX40L Mice
Off-the-shelf Models
Cytokine-Cytokine Receptor
• B- hPD-L1/hTIGIT Mice Humanized Mouse Models
• B- hPD-1/hTIM-3 Mice • B-hIL17A Mice
• B- hPD-L1/hTIM-3 Mice • B-hIL4/IL4R Mice
• B- hPD-1/h4-1BB Mice
• B- hPD-L1/h4-1BB Mice Immuno-Deficient Mouse Models
• B- hPD-1/hCD27 Mice • B-NDG Mice
• B- hPD-L1/hCD27 Mice • B-NDG/b2M Mice
• B- hPD-1/hLAG-3 Mice • B-NDG/ckit Mice
• B- hPD-L1/hLAG-3 Mice • B-NDG/hSIRPα Mice
• B- hPD-1/hCTLA-4 Mice
• B- hPD-L1/hCTLA-4 Mice Humanized Cancer Cell Lines
• B- hPD-1/hGITR Mice • B-hPD-L1 MC38 Cells
• B- hPD-1/hBTLA Mice • B-hCD47 MC38 Cells
• B-hLAG3/hCTLA-4 Mice • B-hTnfrsf14 (HVEM) MC38 Cells
• B-hTIM3/hCTLA-4 Mice • B-hCEACAM1 MC38 Cells
• B-hCD47/hSIRPa Mice • B-hPD-L1 LLC1 Cells
• B-hPD-1/hCD47/hSIRPa Mice • B-hPD-L1 B16F10 Cells
• B-hPD-L1/hCD47/hSIRPa Mice
Cytokine Humanized Humanized Immune Checkpoint
Mouse Models Mouse Models
• B-hIL6 Mice • B-hTNFA/hIL17A Mice
• B-hIL4 Mice • B-hIL23A/hIL12B Mice
• B-hIL4RA Mice • B-hIL23R/hIL12RB1 Mice
• B-hIL2RA Mice • B-hICOS(v2)/hICOSL Mice
• B-hIL17A Mice
• B-hIL17RA Mice
• B-hIL12B Mice
• B-hIL12A Mice
• B-hIL13 Mice
• B-hIL10 Mice
• B-hIL23A Mice
• B-hIL12RB2 Mice
• B-hIL23R Mice
• B-hIL12RB1 Mice
• B-hIL33 Mice
• B-hIL5 Mice
 Innovative Models to Empower Health Sciences
About Biocytogen
Biocytogen is a premier partner that provides a one-stop solution for drug
development, from concept to IND application. With cutting-edge technologies,
state-of-art animal facility, and world-class platforms for efficient antibody drug
development, Biocytogen offers comprehensive in vivo/in vitro preclinical services,
animal model generation, antibody fully human RenMab mouse model, therapeutic
antibody discovery and development, CMC/CDMO, and regulatory affairs support.

Worldwide Customers

50C Audubon Rd, info@biocytogen.com

CONTACT US Wakefield, MA 01880 FOLLOW US
781.587.3558 www.biocytogen.com